|
MechanismOpioid receptors antagonists [+1] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date13 Apr 2006 |
纳曲酮植入剂在阿片类物质成瘾患者康复期志愿者中耐受性及药代动力学研究
[Translation] Tolerance and pharmacokinetics of naltrexone implants in convalescent volunteers from opioid-addicted patients
在阿片类物质成瘾患者康复期志愿者中研究纳曲酮植入剂给药后的耐受性及药动学,为Ⅱ期临床试验制定给药剂量提供依据。
[Translation] To study the tolerability and pharmacokinetics of naltrexone implants in convalescent volunteers of opioid-addicted patients, to provide a basis for the formulation of doses for phase II clinical trials.
100 Clinical Results associated with Shenzhen Civil Life Science Co Ltd
0 Patents (Medical) associated with Shenzhen Civil Life Science Co Ltd
100 Deals associated with Shenzhen Civil Life Science Co Ltd
100 Translational Medicine associated with Shenzhen Civil Life Science Co Ltd